Bayer said today it expected higher one-off burdens in 2025 from provisions for litigations and for buying out executives in its ongoing restructuring programme.
The German maker of drugs, seeds and crop chemicals said it now expects special items to drag earnings before interest, tax, depreciation and amortisation (EBITDA) to between €3.5 billion and €4 billion, worse than a previous forecast range of €2.5 billion-3.5 billion.
It also reported that third-quarter adjusted EBITDA rose 20.8%, citing gains at the Crop Science division and reconciliation effects in accounting.
Quarterly EBITDA, adjusted for special items, came in at €1.51 billion, above the €1.28 billion expected on average by analysts according to a poll posted on the company's website.
